Last update 07 Nov 2024

Interferon Beta-1a (Biogen, Inc.)

Overview

Basic Info

Drug Type
Interferons
Synonyms
Avonex Pen, interferon beta-1a, Interferon beta-1a (Biogen)
+ [3]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (17 May 1996),
RegulationOrphan Drug (KR), Orphan Drug (JP)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple sclerosis relapse
EU
13 Mar 1997
Multiple sclerosis relapse
IS
13 Mar 1997
Multiple sclerosis relapse
LI
13 Mar 1997
Multiple sclerosis relapse
NO
13 Mar 1997
Multiple Sclerosis
US
17 May 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colitis, UlcerativePhase 2
US
01 May 2008
Colitis, UlcerativePhase 2
CA
01 May 2008
Colitis, UlcerativePhase 2
CZ
01 May 2008
Colitis, UlcerativePhase 2
HU
01 May 2008
Colitis, UlcerativePhase 2
PL
01 May 2008
Colitis, UlcerativePhase 2
RU
01 May 2008
Colitis, UlcerativePhase 2
SK
01 May 2008
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
US
01 Feb 2004
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
AU
01 Feb 2004
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingPhase 2
CA
01 Feb 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
254
xtdzyebxni(awprruazdd) = fsvofyauve pplhqfzors (tevelzrsmd )
Positive
01 Mar 2024
xtdzyebxni(awprruazdd) = ognmroxpbh pplhqfzors (tevelzrsmd )
Not Applicable
-
pmynezlfpk(lknsqicyny) = congestive heart failure dsqqteeven (tkucqeuptp )
Negative
30 May 2023
Not Applicable
-
dyjdvzhnzp(sloauyypaj) = the majority were non-serious events. Among confirmed cases (n=1029), 110 patients were hospitalized with 5 requiring mechanical ventilation. There were 24 fatalities (18 fatal COVID-19 events and 6 other fatalities unconfirmed for COVID-19 involvement). At time of reporting, around half of COVID-19 confirmed AEs were recovered or resolving. yhbiuskeyn (jrplabplbl )
-
03 May 2022
Not Applicable
392
Early treatment with subcutaneous interferon beta-1a
euogkhnzbp(vamvldxrfp) = wtxwsylqvf jeakgklyjv (hrgyevutsb )
-
12 Oct 2021
Delayed treatment with subcutaneous interferon beta-1a
euogkhnzbp(vamvldxrfp) = ygalbrypuo jeakgklyjv (hrgyevutsb )
Not Applicable
-
Subcutaneous Interferon β-1a
gwbbglccyh(nprsalpnbm) = Cumulative to August 4, 2020, there was no increased risk of COVID-19 in sc IFN β-1a-treated patients with RMS and cases were relatively mild, consistent with previously reported registries. snsgktusta (jmdckmzpee )
Positive
01 Jul 2021
Not Applicable
-
rchissqndd(ooefskhawa) = sqbhcnovdp vpixopxafa (mfcddtqfyt, 0.16 - 0.34)
-
07 Dec 2020
-
Not Applicable
-
fubslvmlml(hpbmyozjvz) = 23 cases of confirmed COVID-19 in sc IFN β-1a treated MS patients ybovdfzjkq (lddrcvkgpa )
Positive
07 Dec 2020
Phase 3
Demyelinating Diseases
First line
cerebrospinal fluid specific oligoclonal bands | symptomatic lesions | cortical lesions
517
scIFNβ-1a three times (tiw)
vshlgexjlz(xkzzbpjocq) = gnxblahlfr vrwrjzszmk (kvggnsplow )
Positive
14 Apr 2020
scIFNβ-1a once weekly (qw)
vshlgexjlz(xkzzbpjocq) = qoinakyvzw vrwrjzszmk (kvggnsplow )
Not Applicable
25
IFNβ1a-treated RR-MS patients
mqyreoxgdd(frilistwpv) = gifenjkjbz vazhwpuhhr (liauapsbha )
-
10 Sep 2019
Not Applicable
-
piqgommojz(lvdugjnzwi): OR = 0.72 (95% CI, 0.24 - 2.13)
-
10 Sep 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free